Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00727883
- Lead Sponsor
- AstraZeneca
- Brief Summary
Retrospective observational trial on reasons for withdraw of Adjuvant Tamoxifen in Breast Cancer patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 190
Inclusion Criteria
- Breast Ca Patients with surgery and withdraw of adjuvant treatment with Tamoxifen for Tam related AEs
- Documented reasons for treatment withdrawal
Exclusion Criteria
- enrollment in other studies
- treatment withdraw for other causes than Tam related AEs
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of withdraw from adjuvant Tamoxifen due to Tam related AEs January 2003-December 2004
- Secondary Outcome Measures
Name Time Method Types of TAM related AE January 2003-December 2004
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tamoxifen discontinuation in ER-positive breast cancer patients (NCT00727883)?
How does tamoxifen compare to aromatase inhibitors in adjuvant therapy for hormone receptor-positive breast cancer recurrence prevention?
Which biomarkers correlate with early discontinuation of tamoxifen in AstraZeneca's NCT00727883 observational study?
What adverse events led to tamoxifen withdrawal in NCT00727883, and how were they managed in clinical practice?
Are there alternative endocrine therapies or combination strategies for breast cancer patients discontinuing tamoxifen due to resistance or toxicity?